-The Business Standard Drugs are unaffordable, but price control is the wrong answer There is little doubt that medicines in India are too expensive for most of the population. For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey. A World Bank study on the subject found that just out-of-pocket medical costs...

-The Business Standard NPPA to soon notify prices in line with new pharma pricing policy Some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according...

-IPS News ROME: Jassiben, a self-employed potter from Nana Shahpur village in western India, loves summer despite the heat waves and frequent power cuts, because summer days always mean great business. "Poor people like us do not have refrigerators, so they store drinking water in the earthen pots that keep the water cool," says Jassiben, who uses only one name. "This year, the demand has been so high, I am selling at least...

-IPS News ROME: The growing consensus, momentum and commitment to eradicate world hunger may seem overly ambitious in view of the slow progress in reducing the number of hungry people in the world in recent decades. After all, declining food prices in the second half of the 20th century, thanks to increasing production, were not enough to eliminate poverty and hunger in the world. In the 1960s and 1970s, many governments invested a...

-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...